Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

A research team at Umeå University has created advanced light-controlled tools that allow for precise regulation of proteins ...

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ...